Back to Journals » Clinical Ophthalmology » Volume 7

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Authors Nielsen SA, McDonald MB, Majmudar PA

Received 18 September 2012

Accepted for publication 3 November 2012

Published 17 January 2013 Volume 2013:7 Pages 149—156

DOI https://doi.org/10.2147/OPTH.S38279

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Steven A Nielsen,1 Marguerite B McDonald,2 Parag A Majmudar3

1Nielsen Eye Center, Quincy, MA, USA; 2Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 3Chicago Cornea Consultants Hoffman Estates, IL, USA

Background: To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in laser-assisted in situ keratomileusis (LASIK) prophylactic antibiotic regimens.
Methods: Retrospective surveillance of LASIK surgery cases where besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% were prescribed as prophylactic medications. Surgeons from nine US surgical centers provided retrospective case information on surgical outcomes from consecutive cases and reported any adverse events related to the antibacterial used. The primary endpoint was the incidence of adverse drug reactions.
Results: A total of 801 case reports (801 eyes; 534 besifloxacin, 267 moxifloxacin) were obtained. The mean (standard deviation [SD]) age at time of surgery was 36.1 (10.6) years. The mean (SD) duration of antibiotic treatment was 8.6 (2.2) days in the besifloxacin group and 8.0 (2.3) in the moxifloxacin group; daily dosing frequency was higher in the moxifloxacin group preoperatively, on the day of surgery, and postoperatively. There were no reports of adverse drug reactions for the 801 eyes in this surveillance. There were no differences between the besifloxacin and moxifloxacin treatment groups in rates of unexpected corneal findings (2.1% vs 1.5%, P = 0.949). The distribution of final visual acuity for the besifloxacin and moxifloxacin groups were similar (P = 0.793). Most cases had a final visual acuity of 20/20 or better.
Conclusion: In this retrospective surveillance study, the prophylactic use of besifloxacin ophthalmic suspension 0.6% and moxifloxacin ophthalmic solution 0.5% in patients undergoing LASIK surgery was not associated with any adverse drug reactions.

Keywords: Besivance, refractive surgery, adverse drug reactions LASIK, moxifloxacin ophthalmic solution 0.5%, ocular infection prophylaxis

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL

Clinical Ophthalmology 2012, 6:1987-1996

Published Date: 30 November 2012

Readers of this article also read:

The imaging features of metanephric adenoma: a case report and review of literature

Hu YC, Wu L, Yan LF, Zhang W, Cui GB

OncoTargets and Therapy 2015, 8:445-449

Published Date: 13 February 2015

Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients

Maruyama K, Tsuchisaka A, Sakamoto J, Shirato S, Goto H

Clinical Ophthalmology 2013, 7:1441-1446

Published Date: 15 July 2013

Assessment of vitreous drug concentration in the porcine eye following intracameral injection or irrigation with moxifloxacin

Matsuura K, Inoue Y, Sasaki S, Hata Y, Ohmura N, Gotou T

Clinical Ophthalmology 2013, 7:1397-1402

Published Date: 9 July 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:1363-1364

Published Date: 4 July 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2012, 6:1547-1552

Published Date: 21 September 2012